PBM
RNAM

Propel Bio Management’s Avidity Biosciences RNAM Stock Holding History

Propel Bio Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-178,500
Closed -$5.27M – 19
2025
Q1 		$5.27M Hold
178,500
– – 6.12% 7
2024
Q4 		$5.19M Hold
178,500
– – 5.16% 8
2024
Q3 		$8.2M Hold
178,500
– – 4.76% 8
2024
Q2 		$7.29M Hold
178,500
– – 4.73% 8
2024
Q1 		$4.56M Hold
178,500
– – 2.65% 9
2023
Q4 		$1.62M Buy
+178,500
New +$1.19M 1.34% 21

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Propel Bio Management's RNAM Position: Q2 2025 in Review

Propel Bio Management sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 178,500 shares — an estimated $5.27M sold.

Propel Bio Management first reported a position in RNAM in Q4 2023 and held it in 6 quarters. The position peaked at $8.2M in Q3 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • Propel Bio Management reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • Propel Bio Management sold 178,500 Avidity Biosciences shares in Q2 2025, an estimated $5.27M.
  • Propel Bio Management first reported a position in Avidity Biosciences in Q4 2023 and held it in 6 quarters.
  • Propel Bio Management's Avidity Biosciences position peaked at $8.2M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Propel Bio Management's 13F filing for Q2 2025, filed 13 Aug 2025.